Key result
Newer DOACs provide easier, equally effective alternatives to warfarin and heparins despite lacking antidotes.
This review provides a practical guide for physicians on the use and management of newer direct oral anticoagulants.
Supports cautious DOAC adoption amid prescribing challenges; leaves open antidote needs and real-world validation.
Anticoagulation therapy is one of the most important advances in modern medicine, saving thousands of lives from the complications of atrial fibrillation and mechanical heart valves and preventing recurrent venous thromboembolism. Warfarin and heparins have been the predominant anticoagulants used until the past decade. However, the arrival of newer target-specific anticoagulants has brought us easier and equally effective agents, although no specific antidotes are yet available. Being relatively newer drugs, physicians need to be familiar with the various practical issues that may be encountered with the prescription of these drugs, which are summarised in this review.
No takes yet. Share an insight, caveat, or question.
Jecko Thachil (2014) conducted a review in Atrial fibrillation, mechanical heart valves, and venous thromboembolism. Newer direct oral anticoagulants vs. Warfarin and heparins was evaluated. Newer direct oral anticoagulants provide easier and equally effective alternatives to warfarin and heparins, though physicians must manage practical prescribing issues and the lack of antidotes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: